2022年第17届欧洲皮肤病与性病学会春季研讨会

2022年第17届欧洲皮肤病与性病学会(EADV)春季研讨会将于2022年5月12日至14日在斯洛文尼亚卢布尔雅那举行，预计有超过1500名代表出席会议。

欧洲皮肤病与性病学会（EADV）是成立于1987年的一个非营利医学学会，致力于推进皮肤性病学领域的教育、研究与培训的发展。EADV的愿景是成为欧洲首屈一指的皮肤性病学会，其首要目标是改善和提高对患者的护理，为欧洲所有的皮肤性病学家宣提供相关的继续医学教育等。EADV每年在欧洲国家举办一次代表大会和一次春季会议。

European Academy of Dermatology and Venereology (EADV) Spring Symposium 2022
Dates: 12-14 May 2022
Venue: Ljubljana Exhibition and Convention Centre, Ljubljana, Slovenia

摘要征集：

• Abstracts submission opens：  7 December 2021
• Abstracts submission closes：  8 February 2022
• Abstracts evaluation notification：  29 March 2022

点此提交摘要>>>Submit Abstract>>>

Abstracts must be submitted in English. A “blind” selection process will be used. No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.

The title should be as brief as possible but long enough to clearly indicate the nature of the study. 

The title should not be written entirely in capital letters (e.g. NOT LIKE THIS).

The size of the abstract is limited to 3,000 characters (spaces and pictures are not taken in consideration).
The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.

The template of the abstract is structured with the following subheadings:

1. Introduction & Objectives
2. Materials & Methods
3. Results
4. Conclusions

If your abstract describes a case report, you can insert the whole text under the “Results” section.

Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.

Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
No mention of pharmaceutical company names should be included in the abstract either.

The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:

• Is the content interesting, informative, novel or important?
• Are the methods valid, the results relevant and the conclusions justified by the data?
• Are the data presented with clarity and with appropriate structure?
• Is the text written according to proper English grammar and syntactic style?

The authors should specify if they prefer their submission to be considered for:

• e-Poster presentation only
• Oral presentation only
• Indifferent

注册费：

The EADV Congress Ticket includes:

• Name badge
• Admission to EADV Scientific Sessions
• Admission to the Networking Symposium – Thursday 12 May 2022
• Access to e-posters area
• Access to Satellite Symposia Sessions *
• Possibility to collect ECMEC Credits on participation in the EADV Scientific Sessions
• Transportation pass

*  IMPORTANT: Industry Session organisers could limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry session. The organising company reserved the right to refuse single categories, in particular if not adequately related to the objective and purpose of the session.